Steroids are anti-inflammatory medicines used to treat a range of conditions and are usually the first or second line of treatment for hospitalised patients.
CBD has the potential to enhance the therapeutic effect of steroid treatment and also treats the bio-mechanism affected by the COVID-19 virus.
The initial study will evaluate the tolerability, safety, and efficacy of the CBD treatment, for hospitalised patients with COVID-19 Infections.
The trial is being carried out by Stero Biotechs, an Israel-based company focused on CBD formulation research and development, in a collaboration with Mor Research Applications, part of Clalit Health Services.
The small-scale clinical trial at Rabin Medical Center Golda HaSharon Campus is treating 10 patients initially.
The treatment cycle will be for a few weeks with a subsequent follow-up period of the same length.
Stero plans to scale up and expand to a multi-centre clinical trial, with an additional 40 hospitalised patients with COVID-19 Infections, under FDA clinical trial guidelines and regulations.
Founder and CEO David Bassa said: “We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions.
“Hospitalised COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments.
“We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”
Stero is a clinical-stage company involved in the research and development of novel CBD-based treatments.